Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It is primarily used as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS).
## Primary Indications
Adjunctive therapy for seizures in patients with Lennox-Gastaut Syndrome (LGS).
## Adult Dosing
* **Initial Dose:** 5 mg twice daily.
* **Titration:** Gradually increase dose based on clinical response and tolerability.
* **Usual Maintenance Dose:** 10 mg twice daily.
* **Maximum Dose:** 20 mg twice daily (40 mg/day).
## Pediatric Dosing (2 years and older)
* **Initial Dose:** 5 mg once daily.
* **Titration:** Gradually increase dose based on clinical response and tolerability.
* **Usual Maintenance Dose:** 10 mg once daily.
* **Maximum Dose:** 20 mg once daily (20 mg/day).
*Note: For children weighing less than 30 kg, the maximum dose is 10 mg once daily.*
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. Dose reduction may be necessary.
* **Renal Impairment:** Use with caution. Dose reduction may be necessary.
* **Concomitant Medications:** Dose adjustments may be required when used with other CNS depressants or CYP3A4 inhibitors.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory insufficiency.
* Severe hepatic insufficiency.
* Myasthenia gravis.
* Sleep apnea syndrome.
## Adverse Effects
* **Common:** Somnolence, decreased appetite, constipation, aggression, irritability, upper respiratory tract infection, pyrexia, gait disturbance, fatigue, vomiting.
* **Serious:** Suicidal ideation and behavior, severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), respiratory depression, dependence and withdrawal symptoms, paradoxical reactions (increased seizure frequency or severity, agitation, aggression).
## Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other sedatives):** Additive CNS depression, potentially leading to profound sedation, respiratory depression, coma, and death.
* **CYP3A4 Inhibitors (e.g., ketoconazole, ritonavir):** May increase clobazam concentrations.
* **CYP3A4 Inducers (e.g., carbamazepine, phenytoin, rifampin):** May decrease clobazam concentrations.
* **Other Anticonvulsants:** Monitor for efficacy and potential adverse effects, as interactions can occur.
## Monitoring
* Monitor for signs of somnolence and sedation, especially during dose titration or when co-administered with other CNS depressants.
* Assess for behavioral changes, including aggression, irritability, and suicidal ideation.
* Monitor for withdrawal symptoms upon discontinuation.
* Assess seizure frequency and severity.
* Monitor for signs of severe skin reactions.
## Clinical Pearls
* Clobazam is generally considered to have a lower risk of tolerance and dependence compared to other benzodiazepines, but these risks still exist.
* Withdrawal symptoms can occur even with gradual tapering.
* Rapid withdrawal is not recommended and can precipitate status epilepticus.
* Patients and caregivers should be advised about the risk of somnolence and advised to avoid driving or operating heavy machinery until they know how clobazam affects them.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the current prescribing information and relevant clinical guidelines before making any treatment decisions.*
